Call for Abstracts
Acceptance notice will be sent to the first author by email in the end of November.
- Abstract Submission Period
- Call for Abstracts
- Late-breaking Abstracts
- Presidential Session
- Virtual Foreign Contribution Awards (former Travel Awards)
- Publication in "Annals of Oncology"
- Disclosure of Conflict of Interest at 2021 the Japanese Society of Medical Oncology Annual Meeting
- Ethical Principles for Declaring Ethical Matters of your Abstract
- Abstract Submission
- Confirmation / Modification / Deletion of submitted abstract / Additional Submission
- Acceptance/Rejection Notification
- Abstract Submission / Confirmation / Modification / Deletion of Submitted Abstract / Additional Submission
- Inquiry (Technical Problems / Questions)
If you are Japanese, please declare your COI and
submit your abstract at Japanese website.
Abstract Submission Period
Noon, Wednesday, June 17-
Noon, Wednesday, September 16, 2020,
Noon, Wednesday, September 30, 2020 (JST)
Abstract Submission has been closed.
Thank you for your submission.
Call for Abstracts
General Abstract (Oral / Poster Presentation)
JSMO2021 accepts abstracts for general Abstract.
Presentation style for Oral Sessions are either live or on-demand streaming.
Presentation style for Poster Sessions will be on-demand streaming.
Please select the abstract category from the list below. (The 1st & 2nd choices are required.)
Abstract Category for General Abstract
| Category | Sub-Category | Presentation Style |
|---|---|---|
01. Gastrointestinal Cancer |
01-01. Esophageal Cancer 01-02. Gastric Cancer 01-03. Small Bowel Cancer 01-04. Colorectal Cancer 01-05. Other (Appendix Cancer, Anal Cancer, etc.) |
Oral/Poster |
02. Hepatobiliary/ |
02-01. Liver Cancer 02-02. Gallbladder and Biliary Tract Cancer 02-03. Pancreatic Cancer |
Oral/Poster |
03. Lung Cancer/ |
03-01. Early Stage Non-Small Cell Lung Cancer/Perioperative Treatment 03-02. Locally Advanced Non-Small Cell Lung Cancer 03-03. Metastatic Non-Small Cell Lung Cancer/Chemotherapy 03-04. Metastatic Non-Small Cell Lung Cancer/Tyrosine Kinase Inhibitor 03-05. Metastatic Non-Small Cell Lung Cancer/Immunotherapy 03-06. Small Cell Lung Cancer 03-07. Other (Mesothelioma, Thymic Malignancies, etc.) |
Oral/Poster |
04. Hematologic Malignancies |
04-01. Lymphoma 04-02. Leukemia 04-03. Other (Myeloma etc.) |
Oral/Poster |
| 05. Breast Cancer |
05-01. Early Breast Cancer/Perioperative Therapy 05-02. Metastatic Breast Cancer |
Oral/Poster |
06. Gynecologic Cancer |
06-01. Gynecologic Cancer | Oral/Poster |
07. Genitourinary Cancer |
07-01. Genitourinary Cancer | Oral/Poster |
08. Head and Neck Cancer |
08-01. Head and Neck Cancer | Oral/Poster |
09. Rare Cancer/ |
09-01. Pediatric Oncology 09-02. Central Nervous System Tumors 09-03. Endocrine Cancer, Thyroid Cancer, Neuroendocrine Tumor 09-04. Skin Cancer 09-05. Sarcoma 09-06. Germ Cell Tumor 09-07. Cancer of Unknown Primary 09-08. Other |
Oral/Poster |
10. Translational Research/ |
10-01. Basic Research 10-02. Clinical Pharmacology 10-03. Innovative Drug Research & Development 10-04. Molecular Diagnostics/Genomic Medicine 10-05. Translational Research 10-06. Companion Diagnostics 10-07. Developmental Therapeutics 10-08. Other |
Oral/Poster |
11. Palliative Care/ |
11-01. Palliative Medicine 11-02. Symptom Management 11-03. Oral Care for Cancer Patients 11-04. Psycho-Oncology 11-05. Other |
Oral/Poster |
12. Cross-sectional Program |
12-01. Radiation Oncology 12-02. Diagnostic Imaging 12-03. Familial and Hereditary Cancer 12-04. Epidemiology 12-05. Cancer Prevention 12-06. Immunobiology and Immunotherapy 12-07. Drug Therapy 12-08. Other |
Oral/Poster |
13. Multidisciplinary Team Program |
13-01. Interdisciplinary Approach to Cancer Care 13-02. Rehabilitation 13-03. Outpatient Chemotherapy 13-04. Professional Oncology Education 13-05. Oncology Nursing 13-06. Other |
Oral/Poster |
14. Clinical Trial Facilitation Program |
14-01. Biostatistics 14-02. Clinical Trial Support 14-03. Trials in Progress 14-04. Research Ethics 14-05. Health Policy/Regulatory Affairs/Reimbursement 14-06. Health Technology Assessment/Health Economics 14-07. Other |
Oral/Poster |
15. Patient Advocacy/ |
15-01. Patient Advocacy 15-02. Survivorship 15-03. Geriatric Oncology 15-04. Community Cancer Care 15-05. Adolescents and Young Adults with Cancer 15-06. Other |
Oral/Poster |
16. Medical Case Report |
16-01. Rare Cancer 16-02. Lung 16-03. Gastrointestinal Tract 16-04. Hematologic Malignancies 16-05. Breast 16-06. Solid Cancers |
Poster |
17. COVID-19 and cancer |
17-01. COVID-19 and cancer |
Oral/Poster |
18．Miscellaneous |
18-01. Miscellaneous |
Oral/Poster |
(a) Please note that if you select "Trials in Progress," your abstract will NOT be included in electronic program. Your submitted abstracts will be printed and handed out to the participants at the room where you deliver your presentation.
* Abstract Young Investigator Award
- Age limitation: The first author must be under the age 40 (as of February 21, 2021)
- Once you are nominated as a candidate, you will be requested to submit an electronic data for review in December 2020.
- If you would like to be reviewed as a candidate, please check the box to be reviewed as the candidate for the Abstract Young Investigator Award.
* All submitted abstracts will be reviewed by the Peer Review Committee and decided comprehensively based on the study contents, ethical aspects, and etc. You may choose the presentation style (oral or poster) when you submit an abstract. However, please understand that the congress president will make a final decision on the presentation style, presentation session, as well as acceptance/rejection.
Late-breaking Abstracts
JSMO2021 would like to deepen discussions based on the latest research results. We accept such abstracts as "Late-breaking abstracts".
If you are applying for Late-breaking abstracts, please select "Yes" for the question, "Are you applying for late-breaking abstracts?" and submit an outline and predicted results of your research as interim registration in the abstract text box.
Please complete the abstract submission with the latest research results by Friday, October 30, 2020. (You will be notified by the Secretariat to complete the abstract submission at the beginning of October.)
* The accepted results are not influenced even if the actual research results were different from your prediction.
Presidential Session
JSMO2021 will select the abstracts for "Presidential Sessions" from the submitted abstracts this year instead of usual Plenary Session. The selection flow is as follows.
Step 1:
The program committee members choose the following number of abstracts from each category.
38 abstracts in total: 6 abstracts from each Gastrointestinal Cancer and Lung Cancer/Thoracic Cancer, and each 2 abstracts from other category.
Step 2:
Congress president selects 12 abstracts out of 38 abstracts, and the final selection will be made at the program committee.
There is one session a day, and each session is 120 minutes consisting of 4 presentations.
Each presentation is 30 minutes in total (presentation 15 min, Q&A 5 min and discussion 10 min).
Virtual Foreign Contribution Awards
(former Travel Awards)
2021 the Japanese Society of Medical Oncology Annual Meeting (JSMO 20201) will be held as a virtual congress. To support and promote greater interaction with clinicians and researchers from abroad, we will be awarding Virtual Foreign Contribution Awards in lieu of traditional Travel Awards. Exceptional abstracts will be selected, and winners will have their registration fees waived and will be recognized with an award and prize money. Applicants must have submitted an abstract for presentation in a poster or oral session. Applicants who have already submitted their abstracts do not need to re-submit.
Award Details
- Congress registration to JSMO2021 is waived
- Recognition award
- Prize awards ranging from JPY 30,000
Application Acceptance Period
The application period is same as the general abstract submission period.
Noon, Wednesday, June 17, 2020 -
Noon, Wednesday, September 16, 2020, Japan Standard Time
Noon, Wednesday, September 30, 2020 (JST)
The application has been closed. Thank you for your application.
Eligible Applicants
- Applicants must be young overseas doctors/researchers, who live outside of Japan, age 45 years old or younger, as of February 21, 2021 (the last day of JSMO2021).
- Applicants receiving commercial grant support or financial assistance are ineligible.
How to Apply
Please apply by submitting your abstract from the Submission Page (click the "Submit" button below).
Award Notification
Recipients will be notified by e-mail at the end of November, 2020
Publication in "Annals of Oncology"
Abstracts (oral/ poster) submitted in English for JSMO2021 will be published in ESMO/JSMO Scientific Journal, supplement to "Annals of Oncology" (Elsevier).
If you wish to have your abstract published in "Annals of Oncology," please select "Yes".
However, in case that there is any possibility of duplicate publication or encore publication, please refrain from selecting "Yes".
* Terms to be published in Journal "Annals of Oncology" as to poster presentation:
Oral presentations are free of charge but poster presentations are required 5,000JPY of the posting fee of "Annals of Oncology" in addition to the Congress registration fee.
You can cancel publication of the journal after the acceptance notice.
We will contact you to confirm your final intention when the presentation style is decided.
Disclosure of Conflict of Interest at 2021 the Japanese Society of Medical Oncology Annual Meeting
The presenter (the first author) and the principal investigator must disclose the name of any company or for-profit organization related to medicine they have a relationship with, defined as follows: in the following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13) if met. The subject period is from January 1, 2017 - December 31, 2019.
COI Policy (in revision)
Detailed Enforcement Regulations of COI (in revision)
For oral presentation, please use the slide below as a template to disclose conflict of interest.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.
(1) |
If your study for this presentation is supported by research funds |
|---|---|
(2) |
If you are or have been an employee of a company and/or a profit-making organization related to medicine |
(3) |
If you have earned ＞￥1,000,000/year as an officer or advisor of a company and/or a profit-making organization related to medicine |
(4) |
If you hold＞5％ of the stock of a company and/or a profit-making organization related to medicine, or receive dividends ＞￥1,000,000/year |
(5) |
If you have earned ＞￥1,000,000/year as a patent fee from a company and/or a profit-making organization related to medicine |
(6) |
If you have earned ＞￥500,000/year as a lecture fee from a company and/or a profit-making organization related to medicine |
(7) |
If you have earned ＞￥500,000/year as a manuscript fee from a company and/or a profit-making organization related to medicine |
(8) |
If you have research expenses ＞￥1,000,000/year from a company and/or a profit-making organization related to medicine |
(9) |
If you have received ＞￥1,000,000/year as a certain contribution from a company and/or a profit-making organization related to medicine |
(10) |
If you are or have been involved in a certain endowed chair funded by a company and/or a profit-making organization related to medicine |
(11) |
If you have ＞￥1,000,000/year as a fee for expert comment, judgment or testimony in legal proceedings, or others from a company and/or a profit-making organization related to medicine |
(12) |
If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research）equivalent to ＞￥50,000/year from a company and/or a profit-making organization related to medicine |
(13) |
If you are a representative of an organization for clinical study which receives research expenses（donation, contract, others）from a company and/or a profit-making organization related to medicine |
To view the PDF files, you may need, "Adobe Reader"(Download Adobe Reader)
Inquiries regarding COI disclosure
The Secretariat of the Japanese Society of Medical Oncology
E-mail: 
Ethical Principles for Declaring Ethical Matters of your Abstract
In order to review whether your abstract is conformed to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., JSMO ask you to declare the following items:
The content of your declaration will not affect the acceptance or rejection of your abstract.
Please submit to the following:
- Does your study include medical research on human subjects, human material or human data? *Required
- Does your study comply with the Declaration of Helsinki?
- Was your study approved by an institutional review board before starting the research?
Abstract Submission
If you are Japanese, please declare your COI and
submit your abstract at Japanese website.
Guideline
We accept abstracts submitted online only through the submission system.
You may enter the submission page from the "Abstract Submission" button at the bottom of this page.
- Author information and abstracts must be submitted in English.
- Abstract title must be up to 120 single-byte characters. (including spaces)
- Abstract text must be up to 2,000 single-byte characters. (including spaces)
- The maximum of 20 authors (first author & co-authors) can be registered.
- The maximum of 20 affiliations (including the affiliation of the first author) can be registered.
- Please structure your abstract as follows:
Background:
Methods:
Results:
Conclusion: - Any chart or diagram cannot be included.
- Regarding the special characters, please refer ‘How to type special characters’ in the registration page.
- In the registration page, you will be asked to enter the information such as "Application for Late-breaking abstracts", "Application for Virtual Foreign Contribution Awards (former Travel Awards)", "Publication in Annals of Oncology" as well as COI information.
* It is recommended that you prepare your abstract text by Word/ text file in advance, and then copy it on the registration page.
* The abstract registration ID number and your password which will be required to confirm, modify, delete, and add abstracts will be issued and sent to the first author by email when you complete your abstract submission. Please make sure to register the correct email address and keep them by yourself.
The congress secretariat will NOT keep track of your information.
Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission
You can access to confirm/modify/delete/add abstracts during the abstract submission period.
The ID number and password will be required to enter the “Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission” Page.
Acceptance/Rejection Notification
Notification of acceptance/rejection will be sent to the first author by email in the end of November, 2020.
Abstract Submission Page
Confirmation / Modification / Deletion of Submitted Abstract & Additional Submission Page
Deletion / Additional Submission
Inquiries for Abstract Submission
Congress Secretariat
c/o Congrès Inc.
3-6-13, Awajimachi, Chuo-ku, Osaka, 541-0047, Japan
E-mail: jsmo2021-endai@congre.co.jp
